Evidence-Based Management of Melanocytic Neoplasms

In a recent session on evidence-based management of melanocytic neoplasms, dermatologist and dermatopathologist Dr. Jason Lee discussed the evolving standards surrounding the treatment of melanoma, particularly in the context of margins for excision. He noted the inconsistency in clinical practices and the influence of various studies on surgical margin decisions, especially emphasizing the historical perspective on the purported need for 5 cm margins stemming from outdated case studies. Current guidelines suggest a range of margins, with the National Comprehensive Cancer Network (NCCN) recommending anywhere from 0.5 cm to 2 cm based on tumor thickness and location. Dr. Lee highlighted the debate on the overdiagnosis of melanoma in-situ lesions and suggested that not all require aggressive treatment, urging a more individualized approach to their management. He also presented findings about molecular diagnostics and the diagnostic concordance issues among pathologists. Furthermore, he brought attention to the latest adjuvant therapies, such as PD-1 inhibitors, approved for use in preventing recurrence in stage 2B and 2C melanoma, and discussed the need for shared decision-making regarding their use, considering the benefits versus potential side effects. The session concluded with a call for more robust studies to clarify aspects of clinical management for these lesions.